| Ytd | 6.86% | |
| 1y | 102.19% |
| Open | 7.96 | Prev Close | 7.87 | Low | 7.77 | High | 8.15 | Mkt Cap | 178.24M |
| Vol | 17.38K | Avg Vol | 487.50K | EPS | -11.61 | P/E | -0.68 | Forward P/E | -0.87 |
| Beta | 0.80 | Short Ratio | 19.48 | Inst. Own | 48.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 9.12 | 200-d Avg | 7.61 | 1yr Est | 4.50 |
Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being hi
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov
– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 mi
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the
HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with
https://www.sec.gov/Archives/edgar/data/1503802/000119312526204130/d69189ds3.htm
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov
Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Ove
Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and l
HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with
Karyopharm Therapeutics shares fall after mixed Phase 3 SENTRY data show spleen reduction gains but
Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1
Rodman & Renshaw analyst Michael King initiates coverage on Karyopharm Therapeutics (NASDAQ:K
HC Wainwright & Co. analyst Robert Burns reiterates Karyopharm Therapeutics (NASDAQ:KPTI) wit
Karyopharm Therapeutics (NASDAQ:KPTI) sees FY2026 sales of $130.000 million-$150.000 million vs $146
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(5.71) per share which missed th
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Karyopharm Therapeutics (NASDA
Karyopharm Therapeutics (NASDAQ:KPTI) narrows FY2025 sales outlook from $140.000 million-$155.000 mi
RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperf
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2025 sales outlook from $140.000 million-$155.000 mi
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(3.82) per share which missed th
HC Wainwright & Co. analyst Robert Burns upgrades Karyopharm Therapeutics (NASDAQ:KPTI) from
Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Ove
Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and l
Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 m
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov
Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and l
2025 Financial OutlookBased on its current operating plans, Karyopharm expects the following for ful